Intracavernous Injection of Autologous Mesenchymal Stem Cells in the Treatment of Erectile Dysfunction Resistant to Oral Treatment in Patients With Type I Diabetes (MESERIC)

Intracavernous Injection of Autologous Mesenchymal Stem Cells in the Curative Treatment of Erectile Dysfunction Resistant to Oral Treatment in Patients With Type I Diabetes: Dose Escalation Trial

Diabetes is a major concern in public health because of its high frequency and its negative consequences. Erectile dysfunction (ED) is present, regardless of age, in 50 to 75% of men with diabetes. It is related to endothelial dysfunction and a decrease in smooth muscle and nerve cells. In type 1 diabetic patients, ED is part of the chronic complications of microangiopathy. Current therapies are exclusively symptomatic with moderate efficacy, estimated between 44 and 56%. The administration of culture-grown medullary mesenchymal stem cells (MSCs) would be a curative treatment and have the advantage of being single injection.

However, the data in the literature do not allow to define the optimal dose of MSC in this indication. In addition, the feasibility of this procedure is not known at present.

The aim of this study is to evaluate the tolerance and the efficacy of intracavernous injection of autologous MSC (bone marrow-derived MSCs) administered in a 4-dose-escalating design in patients from 18 to 50 years old with complicated type 1 diabetes mellitus and erectile dysfunction.

Study Overview

• Status: Unknown
• Conditions: Diabetes Mellitus, Type 1; Erectile Dysfunction; Stem Cells
• Intervention / Treatment: Drug: Autologous Bone Marrow derived Mesenchymal Stem Cells

• Study Type: Interventional
• Enrollment (Anticipated): 13
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Rabih EL OSTA, MD; Phone Number: +33 03.83.15.33.78; Email: r.elosta@chru-nancy.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Type 1 diabetic man
• Aged from 18 to 50 years
• Having a diabetes evolving for at least 10 years
• Presenting at least one severe manifestation of microangiopathy, with or without dysautonomia: diabetic retinopathy, diabetic or vascular nephropathy, diabetic neuropathy, diabetic foot
• Presenting an erectile dysfunction refractory to oral treatment (sildenafil, tadalafil ...)
• IIEF-5 score less than or equal to 10

Exclusion Criteria:

• Any intercurrent event that does not allow the injection of aMSC
• Violation of the protocol by self erectile dysfunction medication
• Withdrawal of the protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: arm treated with MSC; Type 1 diabetic man; Aged from 18 to 50 years; Having a diabetes evolving for at least 10 years; Presenting at least one severe manifestation of microangiopathy, with or without dysautonomia: diabetic retinopathy, diabetic or vascular nephropathy, diabetic neuropathy, diabetic foot; Presenting an erectile dysfunction refractory to oral treatment (sildenafil, tadalafil ...); IIEF-5 score less than or equal to 10

Drug: Autologous Bone Marrow derived Mesenchymal Stem Cells; Information visit (time 1) Inclusion visit (time 2) Bone marrow extraction (time 3) Treatment and culture of MSC (time 4) Intra-cavernosal injection of autologous MSC (time 5) Follow-up 1 (time 6): control / tolerance visit (andrological clinical examination, EHS and and IIEF-5), 2 weeks after injection; Follow-up 2 (time 7): 12-week evaluation of treatment response: andrological clinical examination, IIEF-5 and EHS score determination & Pharmaco-Doppler; Follow-up 3 (time 8): 24-week evaluation of the response to treatment: andrological clinical examination, determination of IIEF-5 and EHS scores & Pharmaco-Doppler

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the occurrence of clinical adverse event (tolerance) to intracavernous injection of autologous MSC in patients 18 to 50 years of age with complicated type 1 diabetes mellitus with erectile dysfunction refractory to oral treatment.	Occurrence within 2 weeks after the injection of CSMa at the expected dose (10.106, 20.106, 30.106 and 40.106) of a clinical adverse event: thrombosis (s) of the cavernous body, subcutaneous hematoma, induration of the cavernous body , local inflammatory reaction (redness, pain), general effects: fever, chills	within 2 weeks after the injection of CSMa

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of the clinical score IIEF-5 (International Index of Erectile Function-5)	Simplified Scale IIEF-5 with 5 questions (total score between 1 to 25)	12 and 24 weeks after injection
Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of the EHS score		12 and 24 weeks after injection
Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of arterial insufficiency		12 and 24 weeks after injection
Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of venous insufficiency (venous leakage)		12 and 24 weeks after injection
Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the number of bone marrow extraction		19 months
Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the quality of the bone marrow samples		19 months
Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the quality of the cell culture of the marrow of diabetic patients		19 months
Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the cell transport delay (between preparation and injection)		19 months
Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the patient recruitment rate calculated by the ratio between the number of participants and the number of eligible patients		19 months
Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the Injection rate actually achieved		19 months

Collaborators and Investigators

• Sponsor: Central Hospital, Nancy, France

Study record dates

Study Major Dates

• Study Start (Anticipated): June 30, 2018
• Primary Completion (Anticipated): July 30, 2018
• Study Completion (Anticipated): December 31, 2019

Study Registration Dates

• First Submitted: November 22, 2017
• First Submitted That Met QC Criteria: November 28, 2017
• First Posted (Actual): December 5, 2017

Study Record Updates

• Last Update Posted (Actual): December 5, 2017
• Last Update Submitted That Met QC Criteria: November 28, 2017
• Last Verified: November 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Sexual Dysfunctions, Psychological; Sexual Dysfunction, Physiological; Diabetes Mellitus; Diabetes Mellitus, Type 1; Erectile Dysfunction
• Other Study ID Numbers: PHRCI2016/MESERIC-EL OSTA/NK

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No